ArticleScientific reports2017
The Systemic Response to Topical Aldara Treatment is Mediated Through Direct TLR7 Stimulation as Imiquimod Enters the Circulation.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- TLR7-induced murine inflammation results in a global neuroinflammatory response driving neural circuit-specific transcriptomic changes.Scientific reports · 2026Article
- Anti-Psoriatic activity ofOpen veterinary journal · 2026Article
- Topical vaginal drug therapy in cervical cancer management: a review of clinical trials and preclinical evidence.Medical oncology (Northwood, London, England) · 2025Review
- Performance of Imidazoquinoline Glycoconjugate BAIT628 as a TLR7 Agonist Prodrug for Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Transient bacteraemia secondary to imiquimod use as a treatment for cervical high-grade squamous intraepithelial lesions - A case report.Case reports in women's health · 2025Article
- A genetically based computational drug repurposing framework for rapid identification of candidate compounds: application to COVID-19.medRxiv : the preprint server for health sciences · 2025Article
- Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID.International journal of molecular sciences · 2024Review
- Article
- Development of Betulin-Loaded Nanostructured Lipid Carriers for the Management of Imiquimod-Induced Psoriasis.AAPS PharmSciTech · 2024Article
- Evaluation ofMediators of inflammation · 2024Article
- Isostearic acid is an active component of imiquimod formulations used to induce psoriaform disease models.Inflammopharmacology · 2023Article
- Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratioFrontiers in immunology · 2023Article
- Phospholipid-Based Microemulsions for Cutaneous Imiquimod Delivery.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Article
- Inhibition of CtBP-Regulated Proinflammatory Gene Transcription Attenuates Psoriatic Skin Inflammation.The Journal of investigative dermatology · 2022Article
- IL10RB as a key regulator of COVID-19 host susceptibility and severity.medRxiv : the preprint server for health sciences · 2021Article
- Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.Cancer research · 2021Article
- Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.Dermatology (Basel, Switzerland) · 2021Review
- Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.International journal of biological macromolecules · 2020Article
- Psoriatic skin inflammation induces a pre-diabetic phenotype via the endocrine actions of skin secretome.Molecular metabolism · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Topical application of Aldara cream, containing the Toll-like receptor 7/8 agonist Imiquimod, is a widely used mouse model for investigating the pathogenesis of psoriasis. We have previously used this model to study the effects of peripheral inflammation on the brain, and reported a brain-specific response characterised by increased transcription, infiltration of immune cells and anhedonic-like behavior. Here, we perform a more robust characterisation of the systemic response to Aldara application and find a potent but transient response in the periphery, followed by a prolonged response in the brain. Mass spectrometry analysis of plasma and brain samples identified significant levels of Imiquimod in both compartments at molar concentrations likely to evoke a biological response. Indeed, the association of Imiquimod with the brain correlated with increased Iba1 and GFAP staining, indicative of microglia and astrocyte reactivity. These results highlight the potency of this model and raise the question of how useful it is for interpreting the systemic response in psoriasis-like skin inflammation. In addition, the potential impact on the brain should be considered with regards to human use and may explain why fatigue, headaches and nervousness have been reported as side effects following prolonged Aldara use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.